Quest Diagnostics (DGX) stock fell by 0.42% last night, which may be attributed to mixed investor sentiment, as evidenced by some large investors increasing their stakes while others adjusted their positions and analysts issuing varied ratings on the stock.

Quest Diagnostics (DGX) stock fell by 0

Quest Diagnostics (DGX) stock decreased by 1.95% following mixed market reactions to revised earnings estimates and target price adjustments from various equity analysts, despite the company reporting better-than-expected quarterly earnings and revenue.

Quest Diagnostics (DGX) stock decreased by 1

Quest Diagnostics (DGX) stock experienced a decline of 1.95% due to recent insider selling and potential market reactions following their quarterly earnings report, despite reporting higher than expected earnings and revenue growth.

Quest Diagnostics (DGX) stock experienced a decline of 1

Quest Diagnostics (DGX) stock rose 7.08% following the company’s strong second-quarter 2025 results, which exceeded analyst expectations for sales and earnings growth, alongside a raised full-year guidance. The increase in stock price is attributed to robust financial performance, positive sentiment from analysts regarding continuous revenue growth, and the company's confidence in overcoming potential headwinds from tariffs and Medicare legislation.

Quest Diagnostics (DGX) stock rose 7

Quest Diagnostics (NYSE: DGX) stock rose by 6.19% following a strong second quarter performance in 2025 that exceeded analyst expectations and led to a positive revision of its full-year guidance, despite noting potential challenges from tariffs and the Protecting Access to Medicare Act (PAMA). The stock increase reflects investor confidence in the company's financial outlook and growth potential in a favorable market environment.

Quest Diagnostics (NYSE: DGX) stock rose by 6

Quest Diagnostics (DGX) stock is down 0.28%, despite its impressive 493.73% market performance over the past five years; the decline could be attributed to broader market fluctuations or investor reactions to recent news impacting the healthcare sector.

Quest Diagnostics (DGX) stock is down 0

Quest Diagnostics (DGX) stock fell 0.28% following UBS Group's reduction of its target price from $176.00 to $175.00, reflecting a neutral rating on the company amid mixed analyst sentiments.

Quest Diagnostics (DGX) stock fell 0

Quest Diagnostics (NYSE:DGX) stock rose 0.69% due to a consensus recommendation of "Moderate Buy" from analysts and positive quarterly earnings results that surpassed expectations, which may have boosted investor confidence.

Quest Diagnostics (NYSE:DGX) stock rose 0

Quest Diagnostics (DGX) stock rose 0.37% last night, likely due to increased institutional investment and strong quarterly earnings performance, including a reported EPS that exceeded expectations and a favorable outlook from analysts.

Quest Diagnostics (DGX) stock rose 0

Quest Diagnostics (DGX) stock experienced a 0.17% increase, driven by institutional investors increasing their stakes and several brokerages raising their price targets, indicating positive investor sentiment and expected growth in the company's financial performance.

Quest Diagnostics (DGX) stock experienced a 0

Quest Diagnostics (DGX) stock rose by 0.17% likely due to increased institutional investments and positive adjustments in target prices by several research firms following a strong quarterly earnings report that exceeded estimates.

Quest Diagnostics (DGX) stock rose by 0

Quest Diagnostics (DGX) stock decreased by 1.96% likely due to analysts revising ratings and price targets, with some reports suggesting a hold stance after recent estimates adjustments were made by analysts, indicating a cautious sentiment among investors.

Quest Diagnostics (DGX) stock fell by 1.96% likely due to broader market trends or investor profit-taking despite an increase in earnings estimates by analysts at Leerink Partners for FY2025.

Quest Diagnostics (DGX) stock fell by 1

Quest Diagnostics (DGX) stock fell by 1.25% amid mixed analyst reports and insider selling, despite an increase in institutional investment and positive earnings results. The decline could be attributed to profit-taking following recent gains, combined with increased selling pressure from corporate insiders, which may have raised concerns among investors.

Quest Diagnostics (DGX) stock fell by 1.25%, partly due to a downgrade from Wall Street Zen, which changed its rating from "buy" to "hold," amid mixed reactions from various analysts about the company's performance and investments in the first quarter.

Quest Diagnostics (DGX) stock decreased by 1.25% likely due to profit-taking following recent share sales by company insiders and ongoing adjustments in institutional investor stakes, despite positive earnings results and dividend announcements.

Quest Diagnostics (DGX) stock rose by 0.65% due to significant increases in institutional ownership, with several hedge funds boosting their stakes, along with favorable price target adjustments from analysts indicating a positive outlook for the company.

Quest Diagnostics (DGX) stock decreased by 0.84% following a mixed response from analysts regarding its performance and recent insider selling, alongside evolving investment stakes from various institutional investors.

Quest Diagnostics (DGX) stock decreased by 0

Quest Diagnostics (DGX) stock fell by 1.67% recently, despite its significant long-term market outperformance, potentially due to broader market conditions or company-specific factors that may have influenced investor sentiment.

Quest Diagnostics (DGX) stock rose 0.18%, partly due to increased investments from institutional investors and positive analysts' ratings, with multiple firms raising their price targets and expressing bullish sentiments about the company's performance.

Quest Diagnostics (DGX) stock declined by 0.89% primarily due to significant reductions in holdings by Envestnet Portfolio Solutions Inc. and insider sales, indicating potential loss of investor confidence, as well as a downgrade in ratings by multiple research firms.

Quest Diagnostics (DGX) stock declined by 0

Quest Diagnostics (DGX) stock fell by 0.89% after Flagship Harbor Advisors LLC reduced its position in the company by 7.8%, which may have contributed to investor uncertainty and negative sentiment around the stock.

Quest Diagnostics (DGX) stock decreased by 0.69% following recent insider sales and adjustments in institutional holdings, indicating potential investor concerns despite the company recently exceeding earnings expectations.

Quest Diagnostics (DGX) stock fell by 0.69% after the Kentucky Retirement Systems Insurance Trust Fund disclosed a significant reduction in its stake, selling 37.3% of its shares in the company, which may indicate a lack of confidence among institutional investors.

Quest Diagnostics (DGX) stock fell by 1.71%, potentially influenced by a downgrade from "buy" to "hold" by Wall Street Zen and insider selling of shares by company executives, which may have raised concerns among investors.

Quest Diagnostics (DGX) stock fell by 1.71% after several insiders sold a significant number of shares and due to fluctuations in institutional investors' holdings, despite the company's recent positive earnings report and raised price targets from multiple analysts.

Quest Diagnostics (DGX) stock rose by 1.03% due to an increase in institutional investment, including NorthCrest Asset Management raising its position by 5.5%, positive quarterly earnings that beat estimates, and several analysts raising their price targets for the stock.

Quest Diagnostics (DGX) stock rose by 1

Quest Diagnostics (DGX) stock rose by 1.03% last night, reflecting its strong performance over the past five years, during which it has significantly outperformed the market with an annualized return of 313.78%. The stock may have increased due to positive investor sentiment, strong financial results, or favorable market conditions.

Quest Diagnostics (DGX) stock rose by 0.65% due to a significant increase in institutional investments, including a 19.6% boost in holdings by Park Avenue Securities LLC, which reflects strong confidence in the company's performance and financial prospects.

Quest Diagnostics (DGX) stock fell by 0.26% following recent changes in institutional holdings and insider selling activity, indicating potential concerns among investors despite the company's solid earnings report and optimistic broker ratings.

Quest Diagnostics (DGX) stock experienced a decline of 0.26%, influenced by insider selling activities and fluctuating institutional holdings despite positive earnings reports and favorable analyst ratings.

Quest Diagnostics (DGX) stock experienced a decline of 0

Quest Diagnostics (DGX) stock rose by 0.89% following a significant increase in institutional investments, including a 91.9% stake increase by Hennion & Walsh Asset Management, signaling strong market confidence in the company’s financial performance and growth potential.

Quest Diagnostics (NYSE:DGX) stock rose by 0.61% due to an upgrade from Wall Street Zen, which changed its rating from hold to buy, alongside positive earnings results and various price target adjustments by other analysts.

Quest Diagnostics (NYSE:DGX) stock rose by 0

Quest Diagnostics (DGX) stock increased by 0.78% last night, continuing its trend of significant outperformance in the market, attributed to strong financial performance and growth potential.

Quest Diagnostics (DGX) stock increased by 0

Quest Diagnostics (DGX) stock rose by 0.36% last night due to its association with the CDC Foundation, which channels funds from major corporations into public health programs, highlighting the conflict of interest in public health policies influenced by industries like pharmaceuticals and food.

Quest Diagnostics (NYSE: DGX) stock rose by 0.95% following a quarterly earnings report that exceeded estimates, despite analysts slightly lowering their Q3 EPS estimates, indicating a generally favorable sentiment and potential for growth in the company's future earnings.

Quest Diagnostics (NYSE: DGX) stock rose by 0

Quest Diagnostics (NYSE: DGX) stock experienced a decline of 0.5% following a significant decrease in holdings by Lazard Asset Management, which sold over half of its shares in the company during the fourth quarter, contributing to concerns about investor confidence.

Quest Diagnostics (NYSE: DGX) stock experienced a decline of 0

Quest Diagnostics (DGX) stock fell by 0.5% after Gotham Asset Management reduced its stake by 28.1%, prompting speculation about broader investor sentiment amidst mixed activity among institutional investors.

Quest Diagnostics (DGX) stock rose 0.88% last night, continuing its strong performance over the past five years, driven by a significant annualized return and solid market capitalization of $19.47 billion. The stock's increase may be attributed to its consistent outperformance and investor confidence in its financial stability and growth prospects.

DGX

Latest News & Analysis